Clinical trials: Head or Neck Cancer
Thyroid Goiter, Thyroid Nodule
Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it.
Thyroidectomy is considered a common operation with moderate to severe postoperative pain in some patients. Patients are divided into two groups.
- Trial name
- NCT05180214
- Testing
- Bupivacain, Ketorolac
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Sohag University
Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer
Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)
Anti-EGFR (Epidermal Growth Factor Receptor) therapies, namely cetuximab and panitumumab, have become standards in the management of metastatic colorectal and head and neck cancers.
- Trial name
- OPTIMAG (NCT03146338)
- Testing
- Magnesium-rich mineral water (Rozana)
- Where
- 12 sites in France
- Volunteers
- 106 people
- Sponsor
- Weprom
Laryngeal Cancer, Hypopharynx Cancer
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
This study is a prospective, single-arm, single-center, phase II study. The goal of this clinical trial is to explore the therapeutic value of the treatment model of "tislelizumab combined with chemotherapy followed by…
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Trial name
- NCT06554028
- Testing
- chemotherapy TP regimen combined with Tislelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Henan Cancer Hospital
Melanoma, Non Small Cell Lung Cancer
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
This is a prospective cohort study which aims to identify predictive factors of response to PD-1 and PD L1 antagonists authorised for use in France in treatment of melanoma, NSCLC, or HNSCC.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- CHECK'UP (NCT03412058)
- Testing
- Biopsy
- Where
- 19 sites in France
- Volunteers
- 152 people
- Sponsor
- UNICANCER
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Carcinoma of the Head and Neck
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
The primary objective of this study was to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in adults with recurrent or metastatic…
- Trial name
- MASTERKEY232 (NCT02626000)
- Testing
- Talimogene Laherparepvec, Pembrolizumab
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Esophageal Squamous Cell Carcinoma, Esophageal Cancer
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
The primary objective is to compare docetaxel plus cisplatin (DP) versus vinorelbine plus cisplatin (NP) in neoadjuvant chemoradiotherapy, in terms of the overall survival and toxicity in patients with Stage IIB or III squamous…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Oesophageal Cancer
- Trial name
- NCT02465736
- Testing
- Docetaxel, Cisplatin, Radiation
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well bortezomib works in treating patients with metastatic thyroid cancer that did not respond to radioactive iodine therapy.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00104871
- Testing
- Bortezomib
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Nodule, Thyroid Cancer
Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology
1. Principal objective: The primary objective of this study is to validate the diagnostic performance of a Dx15 molecular test based on molecular transcriptomic signatures previously identified in distincts cohorts of samples to…
- Trial name
- CITHY (NCT02225509)
- Testing
- FNA biopsy for thyroid nodule(s)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Diaxonhit
Esophageal Cancer
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1…
- Trial name
- NCT07367516
- Testing
- TQB6411 Injection
- Where
- 30 sites in China
- Volunteers
- 105 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Cancer, Oesophageal Carcinoma
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
This is a Phase 2, open-label, dose optimization/expansion study to assess the preliminary efficacy and safety of SAR445877 as a monotherapy for Chinese participants aged at least 18 years with advanced Gastric…
- Trial name
- NCT07692204
- Testing
- SAR445877
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sanofi
Head and Neck Cancer
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004163
- Testing
- Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
This proposed study will evaluate the efficacy and safety of preoperative administration of Toripalimab or Toripalimab combined with nab-paclitaxel and carboplatin in Head and Neck Squamous Cell Carcinoma (HNSCC) who are about to…
- Trial name
- NCT04807140
- Testing
- Toripalimab, nab-paclitaxel, carboplatin, Toripalimab, Surgical resection
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Squamous Cell Carcinoma of the Head and Neck
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Safety: To characterize the safety of Imprime PGG +…
- Trial name
- NCT03246685
- Testing
- Imprime PGG, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- HiberCell, Inc.
Squamous Cell Carcinoma of Head and Neck
NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
Subjects will receive treatment with nivolumab monotherapy at 240mg flat dose as a 30 minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death…
- Trial name
- NIVACTOR (NCT05802290)
- Testing
- Nivolumab 240 MG in 24 ML Injection
- Where
- 23 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Cervical Cancer, Cancer
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of…
- Conditions
- Cervical Cancer, Cancer, Head and Neck Cancer
- Trial name
- NCT02291055
- Testing
- ADXS11-001, MEDI4736
- Where
- 17 sites in United States
- Volunteers
- 75 people
- Sponsor
- Advaxis, Inc.
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Head and Neck Squamous Cell Carcinoma
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous…
- Trial name
- NCT06308913
- Testing
- INCB081776, Pembrolizumab, Palliative RT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Wisconsin, Madison
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05172258
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 20 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.